;
Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Aldoxorubicin: Phase Ib started

    CytRx Corp. (NASDAQ:CYTR), Los Angeles, Calif. Product: Aldoxorubicin (formerly DOXO-EMCH, INNO-206) Business: Cancer Molecular target: DNA Description: 6-maleimidocaproyl hydrazone prodrug of doxorubicin Indication: …

    Published on 10/27/2014
  • Aldoxorubicin: Phase IIb started

    CytRx Corp. (NASDAQ:CYTR), Los Angeles, Calif. Product: Aldoxorubicin (formerly DOXO-EMCH, INNO-206) Business: Cancer Molecular target: DNA Description: 6-maleimidocaproyl hydrazone prodrug of doxorubicin Indication: …

    Published on 10/27/2014
  • BPSC1001: Phase I started

    NewLink Genetics Corp. (NASDAQ:NLNK), Ames, Iowa Product: BPSC1001, VSV-EBOV Business: Infectious Molecular target: NA Description: Recombinant vesicular stomatitis virus (rVSV) vaccine expressing an Ebola virus protein…

    Published on 10/27/2014
  • Brincidofovir: Phase II started

    Chimerix Inc. (NASDAQ:CMRX), Durham, N.C. Product: Brincidofovir (CMX001) Business: Infectious Molecular target: NA Description: Oral lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations …

    Published on 10/27/2014
  • cAd3-EBO Z: Phase Ib started

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. National Institutes of Health, Bethesda, Md. Product: cAd3-EBO Z Business: Infectious Molecular target: NA Description: Chimp adenovirus type 3 (ChAd3) vector …

    Published on 10/27/2014
  • Collategene beperminogene perplasmid: Phase III started

    AnGes MG Inc. (Tokyo:4563), Osaka, Japan Vical Inc. (NASDAQ:VICL), San Diego, Calif. Product: Collategene beperminogene perplasmid (Collategene, HGF gene therapy) (AMG0001) Business: Cardiovascular Molecular target: …

    Published on 10/27/2014
  • Dupilumab: Phase III started

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Dupilumab (REGN668, SAR231893) Business: Dermatology Molecular target: Interleukin-4 (IL-4) receptor…

    Published on 10/27/2014
  • Hemopurifier: Clinical trial start

    Aethlon Medical Inc. (OTCQB:AEMD), San Diego, Calif. Product: Hemopurifier Business: Infectious Molecular target: NA Description: Extracorporeal device that selectively absorbs viruses and immunosuppressive toxins from …

    Published on 10/27/2014
  • Isavuconazole: Phase III ongoing

    Basilea Pharmaceutica AG (SIX:BSLN), Basel, Switzerland Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Isavuconazole (BAL8557) Business: Infectious Molecular target: 14 alpha-sterol demethylase Description: …

    Published on 10/27/2014
  • Leukocyte interleukin injection: Phase I started

    Cel-Sci Corp. (NYSE-M:CVM), Vienna, Va. Product: Leukocyte interleukin injection (Multikine) Business: Infectious Molecular target: Not applicable Description: Cytokine mixture that includes interleukins, interferons, …

    Published on 10/27/2014
  • Luminate: Phase II started

    Allegro Ophthalmics LLC, San Juan Capistrano, Calif. Senju Pharmaceutical Co. Ltd., Osaka, Japan Product: Luminate (ALG-1001) Business: Ophthalmic Molecular target: Vascular endothelial growth factor (VEGF) Description:…

    Published on 10/27/2014
  • OMS824: Phase II suspended enrollment

    Omeros Corp. (NASDAQ:OMER), Seattle, Wash. Product: OMS824, OMS643762 Business: Neurology Molecular target: Phosphodiesterase-10 (PDE-10) Description: Selective inhibitor of phosphodiesterase-10 (PDE-10) Indication: …

    Published on 10/27/2014
  • SL-401: Phase I/II started

    Stemline Therapeutics Inc. (NASDAQ:STML), New York, N.Y. Product: SL-401 Business: Cancer Molecular target: Interleukin-3 (IL-3) receptor Description: IL-3 receptor targeting agent linked to a truncated diphtheria toxin…

    Published on 10/27/2014
  • ACE-083: Phase I started

    Acceleron Pharma Inc. (NASDAQ:XLRN), Cambridge, Mass. Product: ACE-083 Business: Musculoskeletal Molecular target: Myostatin (GDF8) (MSTN) Description: Ligand trap inhibiting myostatin and activins Indication: Increase …

    Published on 10/20/2014
  • BLZ-100: Phase Ib started

    Blaze Bioscience Inc., Seattle, Wash. Product: BLZ-100 (formerly CyTP 007) Business: Diagnostic Molecular target: NA Description: Combination of an optimized peptide and a near-infrared beacon Indication: Detect and …

    Published on 10/20/2014
  • Cenicriviroc: Phase IIb started

    Tobira Therapeutics Inc., San Francisco, Calif. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Cenicriviroc (formerly TBR-652) Business: Hepatic Molecular target: CC chemokine receptor 5 (CCR5) (…

    Published on 10/20/2014
  • FDX104: Phase II started

    Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), Rehovot, Israel Product: FDX104 Business: Dermatology Molecular target: NA Description: Topical foam formulation of doxycycline Indication: Prevent EGFR inhibitor skin toxicity…

    Published on 10/20/2014
  • Human neural stem cells: Phase I started

    Neuralstem Inc. (NYSE-M:CUR), Rockville, Md. Product: Human neural stem cells (hNSCs) (NSI-566, NSI-566RSC) Business: Neurology Molecular target: Not applicable Description: Human neural stem cells (hNSCs) Indication: …

    Published on 10/20/2014
  • Human neural stem cells: Phase II started

    StemCells Inc. (NASDAQ:STEM), Newark, Calif. Product: Human neural stem cells (HuCNS-SC) Business: Neurology Molecular target: Not applicable Description: Purified human neural stem cells Indication: Treat cervical …

    Published on 10/20/2014
  • LentiGlobin BB305 gene therapy: Phase I started

    bluebird bio Inc. (NASDAQ:BLUE), Cambridge, Mass. Product: LentiGlobin BB305 gene therapy Business: Hematology Molecular target: NA Description: Autologous CD34+ stem cells transduced ex vivo with a lentiviral vector …

    Published on 10/20/2014
  • Mibefradil dihydrochloride: Phase Ib started

    Cavion LLC, Charlottesville, Va. Product: Mibefradil dihydrochloride Business: Cancer Molecular target: Calcium channel T-type Description: T-type calcium channel blocker Indication: Treat recurrent glioblastoma …

    Published on 10/20/2014
  • Mipsagargin: Completed Phase II enrollment

    GenSpera Inc. (OTCBB:GNSZ), San Antonio, Texas Product: Mipsagargin (G-202) Business: Cancer Molecular target: Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII) Description: Prodrug of plant-derived cytotoxin …

    Published on 10/20/2014
  • OTO-104: Phase II/III started

    Otonomy Inc. (NASDAQ:OTIC), San Diego, Calif. Product: OTO-104 Business: Other Molecular target: NA Description: Sustained-release dexamethasone gel delivered via intratympanic injection Indication: Treat acute hearing …

    Published on 10/20/2014
  • Rotavirus vaccine: Phase III started

    Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Rotavirus vaccine Business: Infectious Molecular target: NA Description: Oral, live attenuated tetravalent rotavirus vaccine against serotypes G1, G2, G3 and G4 …

    Published on 10/20/2014
  • SD-101: Phase I/II started

    Dynavax Technologies Corp. (NASDAQ:DVAX), Berkeley, Calif. Product: SD-101 Business: Cancer Molecular target: Toll-like receptor 9 (TLR9) Description: Immunostimulatory sequence (ISS)-based second-generation type C toll…

    Published on 10/20/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993